Question 274 of 433
Should I take a PCSK9 inhibitor to keep my arteries young?
The short answer
A PCSK9-directed treatment can be valuable when cardiovascular risk and LDL levels justify it. The indication and outcome evidence belong to the particular drug, not just the family name.
PCSK9 affects how the liver clears LDL particles. People with certain inherited loss-of-function variants have lower lifetime LDL exposure and substantially lower coronary risk. That supports the biology; it does not replace a drug trial.
The monoclonal antibodies evolocumab and alirocumab have randomized cardiovascular-outcome evidence in selected high-risk patients. Evolocumab’s VESALIUS-CV trial also supports prevention of first major events in a specifically selected high-risk population without a prior heart attack or stroke. That is not the same as benefit for every healthy adult.
Inclisiran, given twice yearly after its initial doses, lowers LDL by a different mechanism. Enlicitide, the oral option approved in 2026, also lowers LDL substantially. Do not attribute the antibodies’ completed outcome trials to these products; their own clinical-event studies must answer that question.
Choice depends on established disease, inherited risk, achieved LDL on tolerated treatment, access, adherence, and preference. A statin, often with ezetimibe, remains an effective and inexpensive starting point for many. A more convenient formulation is valuable when it helps the right person sustain appropriate treatment.
“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer
ROBUST for specific PCSK9 antibody outcome trials; LDL lowering does not establish identical outcome evidence for every formulation.Evidence grade (draft mapping)ARobust human trialsPart 19, Q274 · Sources: R4, R13, R18
Sources cited
- R4 Blumenthal RS et al. 2026 ACC/AHA multisociety Guideline on the Management of Dyslipidemia. Journal of the American College of Cardiology. 2026. doi:10.1016/j.jacc.2025.11.016. Link pending verification
- R13 US Food and Drug Administration. FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol. July 2026. Link pending verification
- R18 ORION-4 Collaborative Group. HPS-4/TIMI 65/ORION-4 trial design, recruitment, and baseline characteristics. American Heart Journal. 2026;303:107546. doi:10.1016/j.ahj.2026.107546. Link pending verification
From Longevity Unmasked by Afshine Ash Emrani, MD, FACC. Medical disclaimer. This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship. Nothing here is meant to diagnose, treat, cure, or prevent any disease. Medicine is personal: a test, drug, supplement, or exercise plan that helps one person can harm another. Do not start, stop, or change any medication or treatment because of something you read in these pages. Talk with a licensed clinician who knows your history first. If you think you are having a medical emergency, call 911. The author disclaims responsibility for any loss or harm arising from use of the information in this book.